TD ASSET MANAGEMENT INC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.

Quarter-by-quarter ownership
TD ASSET MANAGEMENT INC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$4,146,529
+290.7%
139,426
+136.7%
0.01%
+400.0%
Q2 2023$1,061,378
+139.5%
58,900
+113.4%
0.00%0.0%
Q1 2023$443,256
+111.1%
27,600
+227.8%
0.00%
Q2 2019$210,000
-27.1%
8,419
-12.5%
0.00%
-100.0%
Q4 2018$288,000
-8.0%
9,619
-11.9%
0.00%
Q3 2018$313,00010,9190.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders